Laurence A. Turka - Jan 29, 2022 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role
Chief Scientific Officer
Signature
/s/ Joanne M. Protano, Attorney-in-Fact
Stock symbol
RUBY
Transactions as of
Jan 29, 2022
Transactions value $
-$16,544
Form type
4
Date filed
2/1/2022, 08:18 PM
Next filing
Jan 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RUBY Common Stock Options Exercise +7.44K 7.44K Jan 29, 2022 Direct F1
transaction RUBY Common Stock Sale -$16.5K -2.52K -33.84% $6.57* 4.92K Feb 1, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Restricted Stock Units Options Exercise $0 -7.44K -25% $0.00 22.3K Jan 29, 2022 Common Stock 7.44K Direct F1, F4
transaction RUBY Stock Option (Right to Buy) Award $0 +144K $0.00 144K Jan 31, 2022 Common Stock 144K $6.75 Direct F5
transaction RUBY Restricted Stock Units Award $0 +34.5K $0.00 34.5K Jan 31, 2022 Common Stock 34.5K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.70, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
F5 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
F6 The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.